ADCT

$1.55-5.49%visit website

ADC Therapeutics SA

Market Cap

$198M

Live price × SEC shares (Aug 3, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

1.80

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

2.5

TTM to Jun 2026 · revenue

P/B

N/M

TTM to Jun 2026 · negative equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	16,427	23,058	20,851	19,248	79,584
Research & development	26,803	18,184	19,877	17,366	82,230
Operating income	(30,969)	(17,919)	(25,245)	(25,414)	(99,547)
Interest expense	13,392	13,014	12,349	13,508	52,263
Pretax income	(40,966)	(6,813)	(32,968)	(16,565)	(97,312)
Income tax	0	(404)	0	0	(404)
Net income	(40,966)	(6,409)	(32,968)	(16,565)	(96,908)
EPS (basic) ($)	(0.30)		(0.21)	(0.11)	(0.58)
EPS (diluted) ($)	(0.30)		(0.21)	(0.11)	(0.58)
Weighted avg. shares (basic)	136,447		154,142	155,016
Weighted avg. shares (diluted)	136,447		154,142	155,016

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 13, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 10 more quarters, back to Mar 2023, with Tormere Pro.

Corporate Events (8-K)

1 filing in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Nov 4, 2026 accepted 4:00 PM ET	2.02Earnings release7.01Reg FD disclosure8.01Other events	Document SEC ↗

Signals

purchases / sales, 90d

Short Volume

71%

W/W +52.7pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-04-02	2026-04-02	Redmile Group, LLC	10% Owner	Sale	5.16M	$3.28	$16.93M	10.27M	View
2026-04-01	2026-04-02	Redmile Group, LLC	10% Owner	Sale	331.8K	$3.80	$1.26M	12.79M	View
2026-03-31	2026-04-02	Redmile Group, LLC	10% Owner	Sale	384.6K	$3.75	$1.44M	12.96M	View

Recent News

AIGH Capital Management LLC Acquires New Shares in ADC Therapeutics SA $ADCT

MarketBeat · 2026-11-06

BioAge Labs, Inc. (BIOA) Reports Q3 Loss, Misses Revenue Estimates

Yahoo · 2026-11-05

ADC Therapeutics SA Announces ZYNLONTA Clinical Trial Data and Financial Restructuring

Fintel · 2026-11-05

ADC Therapeutics SA (ADCT) Discusses ZYNLONTA Data at ASH and Strategic Financial Restructuring Transcript

SeekingAlpha · 2026-11-04

ADC Therapeutics Reports Strong Lymphoma Responses, Plans Phase III Study

Yahoo · 2026-11-04

ADC Therapeutics Announces Abstracts at the 68th ASH Annual Meeting Highlighting Breadth of ZYNLONTA® Clinical Program

Yahoo · 2026-11-04

ADC Therapeutics to Present at November Investor Conferences

Yahoo · 2026-11-03

Boston and London host ADC Therapeutics CEO's November talks.

Stock Titan · 2026-11-03

ADC Therapeutics Announces New Employee Inducement Grant

Yahoo · 2026-11-02

ADC Therapeutics to Announce Third Quarter 2026 Financial Results on November 9, 2026

Yahoo · 2026-11-02

ADC Therapeutics Announces ZYNLONTA® Updates in Japan

Yahoo · 2026-10-29

ADC Therapeutics' Licensing Partner Tanabe Pharma Files Japanese Marketing Authorization Application For ZYLONTA For Relapsed Or Refractory Diffuse Large B-Cell Lymphoma

Benzinga · 2026-10-29

NeoGenomics (NEO) Q3 Earnings and Revenues Beat Estimates

Yahoo · 2026-10-28

ADC Therapeutics Cuts Debt, Extends Runway Ahead of Key Drug Data, RBC Says

Yahoo · 2026-10-09

ADC Therapeutics: Shares Spike On Restructuring, But Safety Fears Undermine Bull Thesis

Seeking Alpha · 2026-10-09

Informational purposes only, not investment advice.

Date	Insider	Type	Shares	Value
2026-04-02	Redmile Group, LLC	S	2,634,506	$9M
2026-04-02	Redmile Group, LLC	S	2,529,491	$8M
2026-04-01	Redmile Group, LLC	S	169,265	$643,037.74
2026-04-01	Redmile Group, LLC	S	162,517	$617,402.08
2026-03-31	Redmile Group, LLC	S	196,229	$736,251.21

ADCT

Financial Statements

Corporate Events (8-K)

Signals

Factor Profile

Recent News

ADC Therapeutics SA (ADCT)

Reporting Insiders

Factor Profile

Corporate Events (8-K)